期刊文献+

平均血小板体积与阿司匹林抵抗的关系 被引量:2

下载PDF
导出
摘要 目的探讨平均小板体积(MPV)与阿司匹林抵抗(AR)的关系。方法选取2006年10月~2007年4月102例常规服用阿司匹林患者的临床资料。收集所有入选患者的血小板聚集试验结果和试验前后1周之内的血常规报告,从中获取患者的血小板平均聚集率和MPV数据。根据血小板平均聚集率将102例患者分为AR组、阿司匹林半抵抗组(ASR组)和阿司匹林敏感组(AS组),对各组MPV进行比较分析。结果102例入选者中AR组21例,ASR组41例,AS组40例。三组MPV分别为(8.65±0.94)、(8.43±0.45)和(7.95±0.84)fL,其中AR组的MPV显著大于AS组(P<0.05)。结论MPV临床可用于预测AR。提示AR的发生可能与血小板更新率增加有关。
出处 《上海交通大学学报(医学版)》 CAS CSCD 北大核心 2008年第2期222-223,227,共3页 Journal of Shanghai Jiao tong University:Medical Science
基金 上海市卫生局基金(044018)~~
  • 相关文献

参考文献7

  • 1Binder HM, Schuster JE, Binder CS,et al. Correlation of thrombosis with increased platelet turnover in thrombocytosis [J].Blood, 1998,91 (4) :1288 - 1294.
  • 2MeCabe DJ, Harrison P, Sidhu PS, et al. Circulating reticulated platelets in the early and late phases after isehaemie stroke and transient isehaemie attack [J].Br J Haematol, 2004,126 (6):861 - 869.
  • 3Kamath S, Blann AD, Lip GY. Platelet activation: assessment and quantification[J]. Eur Heart J,2001,22(17) :1561 -1571.
  • 4Hankey GJ, Eikelboom JW. Aspirin resistance[J]. Lancet, 2006,367(9510) :606-617.
  • 5Zimmermann N, Wenk A, Kim U, et al. Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery[J]. Circulation, 2003,108 (5) :542 - 547.
  • 6Yang A, Pizzulli L, Luderitz B.Mean platelet volume as marker of restenosis after pereutaneous transluminal coronary angioplasty in patients with stable and unstable angina peetoris[J].Thromb Res,2006,117(4) :371 -377.
  • 7Guthikonda S, Lev EI, Patel R, et al. Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin[J].J Thromb Haemost, 2007,5 (3) :490 - 496.

同被引文献29

  • 1周小峰.脑梗死患者阿司匹林抵抗的临床特征[J].医学信息(医学与计算机应用),2014,0(35):76-77. 被引量:1
  • 2辛晓敏,金英玉,张云平,关秀茹,李洁.阿司匹林抵抗与尿11-脱氢-血栓素B_2的检测及相关性研究[J].中华检验医学杂志,2005,28(9):919-921. 被引量:10
  • 3张利伟,王学锋,王鸿利.阿司匹林抵抗及其实验监测[J].诊断学理论与实践,2006,5(5):439-442. 被引量:10
  • 4苏冠华,王朝晖,丁艳萍.阿司匹林抵抗与血清血栓素B_2的相关性研究[J].中国心血管杂志,2006,11(6):443-445. 被引量:2
  • 5Collaborativemeta-analysis of randomized trials ofantiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients [ J ]. BMJ, 2002,324 : 71- 86.
  • 6Antithrombotic Trialists Collaboration. Collaborative meta analysis of random is edtrial of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients [ J ]. Br Med J ,2002,324 (7329) :71-86.
  • 7Gum PA, Kottke-Marchant K, Poggio ED, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol,2001,88 :230-235.
  • 8Lev El, Patel RT, Maresh KJ, et al. Aspirin and clopigrel drug response in patients undergoing percutaneous coronary intervention : the role of dual drug resistance [ J ]. J Am Coil Cardiol,2006,47( 1 ) :27-33.
  • 9Gonzalez-Goneheto R, Rivera J, Corral J, et al. Biological assessment of aspirin efficacy on healthy individuals heterogeneous response or aspirin failure [ J ]. Stroke ,2005,36 : 276.
  • 10Cooke GE, Bray PF, Hamlington JD, et al. P1A2polymorphism and efficacy of aspirin [ J ]. Lancet, 1998, 351: 1253.

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部